M
Magnolia Neurosciences
Drug discovery and development company for neuroprotective medicines
About Magnolia Neurosciences
Magnolia Neurosciences Corporation was a biotechnology firm established to develop a new class of neuroprotective medicines aimed at treating neurodegenerative diseases and neuronal injuries. The company was co-founded in August 2018 by life science investment firm Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center. The scientific foundation for Magnolia stemmed from discoveries made by researchers within MD Anderson's Therapeutics Discovery division, including Philip Jones and Jim Ray. Their research into chemotherapy-induced conditions like peripheral neuropathy and "chemo brain" revealed that the underlying mechanisms of neurodegeneration were common to chronic diseases such as Alzheimer's and Parkinson's.
The company launched with a significant $31 million Series A financing round, attracting investment from a syndicate of prominent venture capital firms and corporate venture arms of major pharmaceutical companies. Investors included AbbVie Ventures, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation, and Pfizer Ventures, among others. The company's strategy focused on developing drug-like small molecules that could block specific components of programmed cell death, a process that becomes reactivated in certain neurological conditions. The goal was to create therapies that could slow or halt neuronal loss, preserving brain tissue and function. Magnolia aimed to rapidly advance these therapies into clinical proof-of-concept for conditions with high unmet patient needs.
The business operated as a drug discovery and development company, with its headquarters in New York City and a subsidiary, Magnolia Tejas Corporation, in Houston, Texas. Its business model was centered on translating preclinical research into commercially viable therapeutics for serious Central Nervous System (CNS) diseases. While the company generated significant initial interest and funding, public information about its progress ceased after its initial launch phase, and its corporate website is no longer active as of early 2024.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCEquity / VC | Jul 2020 | $5M | $20M | Undisclosed | — |
| SERIES A✓Equity / VC | Aug 2018 | $31M | $124M | ARCH Venture Partners · Eli Lilly · Pfizer · Abbvie Biotech Ventures | ↗ |
Growth signals
Latest recorded traffic for Magnolia Neurosciences is 240 monthly website visits, down 7.7% over the last three months. Magnolia Neurosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Magnolia Neurosciences in the New York City ecosystem
The Magnolia Neurosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Accelerator Life Science Partners
ARCH Venture Partners
Eli Lilly
Pfizer
Abbvie Biotech Ventures
Alexandria Venture Investments
Partnership Fund for New York City
Johnson & Johnson Innovation
Other known investors1 additional known investor
180 Degree Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Magnolia Neurosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Magnolia Neurosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








